Longevity M&A: what is happening now?

What are the latest M&A deals in the longevity market?

When we look at all the M&A deals in the longevity market over the last 24 months, we find 25 transaction records across longevity clinics, preventive diagnostics, epigenetic testing, geroscience biotech, reproductive longevity, wearables, metabolic health, and health-data infrastructure.

Date	Target	Acquirer	Value	Strategic rationale	Status and additional comment
May 2026	Turn Biotechnologies age-reversal assets	Daewoong Pharmaceutical	Undisclosed	Acquire mRNA partial-reprogramming assets for age-reversal and cellular function restoration	Closed / announced. Looks more like a selective asset grab than a full-company growth acquisition
Apr. 2026	Tally Health	Infinite Epigenetics / TruDiagnostic	Undisclosed	Consolidate epigenetic biological-age testing and consumer longevity recommendations	Closed / announced. One of the clearest biological-age testing consolidation deals
Apr. 2026	Galen AI technology and team	ŌURA	Undisclosed	Add medical-record, lab, medication, and wearable-data integration to Oura’s health companion	Closed / announced. Oura moves deeper into clinical context
Mar. 2026	Eos SENOLYTIX	Pulmatrix	$19M financing reference	Take gerotherapeutic mitochondrial-dysfunction pipeline public through reverse merger	Announced / pending. Core anti-aging biotech, but mostly financing-led
Mar. 2026	Doublepoint	ŌURA	Undisclosed	Add AI gesture-recognition technology for future wearable interactions	Closed / announced. More wearable AI than pure longevity, but part of Oura’s wider health stack
Feb. 2026	BioDesign	Agentis Longevity	Undisclosed	Expand personalized longevity and performance medicine clinic footprint	Closed / announced. Part of Agentis’ roll-up sequence
Jan. 2026	Arete Wellness	Agentis Longevity	Undisclosed	Add performance-driven health, recovery, diagnostics, hormones, and peptide therapies	Closed. Reinforces Agentis’ clinic-platform strategy
Dec. 2025	HerMD	Joi + Blokes	Undisclosed	Build a national virtual women’s health platform around menopause, hormones, longevity, and healthspan	Closed / announced. Strong women’s longevity and virtual-care deal
Jul. 2025	ThriveMD non-clinical assets	Novellum Longevity / Boyne / Platt Park	Undisclosed	Create a PE-backed MSO for functional wellness and longevity clinics	Closed / platform formed. Another clear clinic roll-up move
Jul. 2025	THPlasma reverse merger	Longevity Health Holdings / True Health	$76.9M reference	Combine plasma centers with healthy-aging, regenerative, diagnostics, and nutrition platform	Cancelled. Ambitious, but execution failed
Jun. 2025	Minovia Therapeutics	Launch One Acquisition Corp.	$180M SPAC reference	Take mitochondrial augmentation platform public	Announced / not verified closed. Closer to public-listing finance than normal strategic M&A
Jun. 2025	SomaLogic	Illumina	$350M upfront + up to $75M	Add proteomics to multiomics infrastructure relevant to aging biology	Announced / not verified closed. Adjacent to longevity, but important for the measurement layer
May 2025	Dorian Therapeutics	Altos Labs	Undisclosed	Add senescence-targeting capabilities to cellular rejuvenation platform	Closed / announced. One of the strongest geroscience acquisitions in the dataset
May 2025	Ezra	Function Health	Undisclosed	Combine full-body MRI with lab testing for preventive health	Closed / announced. Major consumer preventive-diagnostics deal
Apr. 2025	Oviva Therapeutics	Granata Bio	Undisclosed	Add ovarian-aging therapeutics to women’s reproductive health pipeline	Closed / announced. Core reproductive-longevity biotech
Apr. 2025	Longevity Health Holdings	20/20 GeneSystems / 20/20 BioLabs	About $50M reference	Combine diagnostics, bio-aesthetics, and nutrition under healthy aging	Cancelled. Failed before the later THPlasma transaction
Mar. 2025	Mantality	Agentis Longevity	Undisclosed	Build longevity clinics around hormone optimization and medical weight loss	Closed. Foundational clinic-platform deal
Mar. 2025	Pro2col / Pruvit assets + Link BioSciences interest	Herbalife	Undisclosed	Add ketone products and biomarker-driven longevity protocols	Announced. Adjacent consumer nutrition and protocol deal
Mar. 2025	BellSant	Hundred Health	Undisclosed	Add longevity research data and personalization engine to AI health platform	Closed / announced. Useful data and personalization acquisition
Feb. 2025	Sparkd	Chi Longevity	Undisclosed	Add cognitive and physical performance training to longevity clinic model	Closed / announced. Clinic-services capability acquisition
Jan. 2025	ivee	Hone Health	Undisclosed	Add at-home clinical services to preventive and longevity telehealth	Closed / announced. Funding and acquisition announced together
Jan. 2025	Elevai skincare assets	Carmell / Longevity Health Holdings	Undisclosed upfront; earnout disclosed	Add exosome-based skin and hair products to regenerative healthy-aging platform	Closed. One of the few deals with revenue and earnout details
Dec. 2024	Agentis Longevity platform / Mantality	Shore Capital Partners	Undisclosed	Launch PE-backed longevity care platform	Closed / platform launched. Sets up later roll-up activity
Oct. 2024	Sparta Science	ŌURA	Undisclosed	Add enterprise human-performance analytics to Oura’s B2B health stack	Closed / announced. Oura’s third acquisition in two years
Sep. 2024	Veri	ŌURA	Undisclosed	Add metabolic-health and CGM-based nutrition insights to wearable health platform	Closed / announced. Early move into metabolic longevity

Is longevity M&A really active now?

Yes. Longevity M&A is active enough to be a real market, but still too young to look like mature healthcare or pharma M&A.

The first thing we see is the count: 25 transaction records in 24 months, or roughly one visible deal per month. For a young category, that is real activity. More importantly, 19 of those 25 deals are core longevity, meaning the targets are directly tied to longevity clinics, healthy aging, geroscience, biological-age testing, ovarian aging, regenerative medicine, or healthspan. This is not just a loose collection of wellness deals with a longevity label added afterward.

The mix also tells us where the market actually is. Buyers are acquiring clinics, diagnostics, epigenetic tests, full-body MRI, metabolic data, clinical-data integration, and selected aging-biology assets. Very few deals look like large, clean, big-pharma-style takeovers. Most look like platform formation, add-on buying, asset purchases, reverse mergers, or targeted capability acquisitions.

That makes the market more practical than hype-driven. Buyers are picking up pieces they can integrate, bill, measure, or scale. Longevity M&A is already real, but it is still being built from the ground up.

If you want more recent data on this point, please see our latest longevity market report.

Is longevity M&A accelerating recently?

No. When we compare recent longevity M&A activity with the previous period, the market is clearly not accelerating.

The last 12 months produced 10 transaction records, while the previous 12 months produced 15. That is a decline of 5 deals, or about -33%. Put differently, the last 12 months had only two-thirds as many deals as the 12 months before.

The timing makes the story even clearer. The busiest stretch was Q1 and Q2 2025, with 13 transaction records across Hone / ivee, Hundred / BellSant, Agentis / Mantality, Function / Ezra, Altos / Dorian, Granata / Oviva, Illumina / SomaLogic, Minovia, and others. After that, the market did not vanish, but it became thinner. The later period is mostly Agentis, Oura, Infinite Epigenetics, Daewoong, Pulmatrix, and Joi + Blokes.

The market has moved from a broad wave to a narrower buyer set. The strongest acquirers are still active, but the easy “everyone is testing the category” phase looks over. The better conclusion is that longevity M&A has cooled, while serious buyers are still selectively adding pieces.

Is longevity M&A still happening these days?

Yes. Longevity M&A is still happening these days, but the latest deals look more targeted than the earlier wave.

The last 6 months include 7 transaction records: Agentis / Arete, Agentis / BioDesign, Oura / Doublepoint, Pulmatrix / Eos SENOLYTIX, Oura / Galen AI, Infinite Epigenetics / Tally Health, and Daewoong / Turn Bio assets. That is still a meaningful pace for a market this young.

The last 3 months are quieter, with 3 transaction records, but they are useful transactions to read. Infinite Epigenetics / Tally is a direct biological-age testing consolidation deal. Oura / Galen AI connects wearable data with clinical data. Daewoong / Turn Bio brings an established pharmaceutical company into age-reversal assets.

The latest deals do not feel random. They are concentrated around specific needs: clinic expansion, biological-age testing, wearable health infrastructure, gerotherapeutics, and partial reprogramming. The market has less noise than it had in early 2025, but the remaining activity is more focused.

What are buyers actually buying in longevity now?

Buyers in longevity are mostly buying delivery, measurement, data, and selected science assets.

Delivery is the clinic layer. Agentis bought Mantality, Arete, and BioDesign. Novellum was formed around ThriveMD assets. Hone bought ivee. Chi Longevity bought Sparkd. Joi + Blokes bought HerMD. These companies are buying patient access, services, protocols, clinicians, locations, virtual-care reach, and recovery and performance offerings.

Measurement is the second big layer. Function Health bought Ezra to combine labs with full-body MRI. Infinite Epigenetics bought Tally Health to connect epigenetic testing with consumer-facing recommendations. Illumina announced SomaLogic to strengthen proteomics and multiomics. Hundred Health bought BellSant for longevity research data and personalization. The common thread is simple: longevity businesses need ways to prove whether anything is changing.

The science layer is smaller, but it carries a lot of strategic weight. Altos bought Dorian for senescence biology. Granata bought Oviva for ovarian aging. Pulmatrix announced Eos SENOLYTIX around mitochondrial dysfunction. Minovia pursued a SPAC around mitochondrial augmentation. Daewoong acquired Turn Bio age-reversal assets.

Are longevity clinics becoming the main M&A category now?

Yes. Longevity clinics look like the most concrete M&A category in the market right now.

Agentis is the clearest example. Shore Capital launched the platform around Mantality, then Agentis added Arete Wellness and BioDesign. That gives us a proper sequence: platform formation, then repeat add-on activity, all around hormone optimization, diagnostics, weight management, recovery, performance medicine, peptides, and personalized longevity care.

Other deals point in the same direction. Novellum Longevity was formed around ThriveMD’s non-clinical assets to scale a clinic MSO. Hone bought ivee to add at-home clinical services. Joi + Blokes bought HerMD to expand women’s virtual care around menopause, hormones, and healthspan. Chi Longevity bought Sparkd to add cognitive and physical performance programming.

Clinics are attractive because they already have customers, services, and revenue pathways. Biotech assets can be more exciting, sure, but clinics are easier to consolidate today. For the next phase of longevity M&A, clinics look like the most repeatable roll-up opportunity.

If you want more recent data on this point, please see our latest longevity market report.

Are wearables becoming serious longevity acquirers now?

Yes. Wearables are becoming serious longevity acquirers, and Oura is doing the clearest work here.

Oura made 4 relevant acquisitions in the 24-month window: Veri, Sparta Science, Doublepoint, and Galen AI. Veri adds metabolic-health and CGM-based nutrition context. Sparta Science adds performance analytics. Doublepoint adds gesture recognition. Galen AI adds medical records, labs, medications, and clinical-data integration.

The sequence matters more than any single acquisition. Oura started from daily biometric tracking, but these deals push it toward a broader preventive-health platform. A ring can track sleep and recovery; with metabolic data, performance analytics, and clinical records, it starts to become a much richer health companion.

The timing also shows commitment. Oura bought Veri and Sparta in late 2024, then Doublepoint and Galen AI in 2026. That is not a one-off experiment. Oura is repeatedly buying the pieces needed to connect consumer wearables with more serious health infrastructure.

The likely direction is clear: wearables want to own the consumer health data layer before clinics, labs, and insurers do.

Is longevity diagnostics consolidating now?

Yes. Longevity diagnostics is consolidating around a basic commercial problem: consumers need proof before they keep paying for longevity interventions.

Function Health / Ezra is the cleanest example. Function already sits around lab testing and proactive health. Ezra adds full-body MRI. Together, that creates a broader preventive-health product: blood markers plus imaging. The consumer gets a more complete check, and the company gets a stronger reason for repeat engagement.

Infinite Epigenetics / Tally Health is the biological-age version of the same idea. Infinite / TruDiagnostic brings epigenetic testing. Tally brings a consumer longevity brand and recommendation layer. The business opportunity is not just selling one test. It is building a loop: test, explain, recommend, retest.

Other deals reinforce the measurement thesis. Illumina / SomaLogic adds proteomics and multiomics. Hundred / BellSant adds research and personalization data. Herbalife’s Pro2col / Pruvit / Link BioSciences transaction adds biomarker-driven protocol technology to a nutrition platform.

This is where longevity starts becoming more disciplined. The companies that can measure change will have an advantage over companies just selling “wellness” benefits.

Is geroscience biotech hot again now?

Geroscience biotech is strategically alive, but this does not look like a hot, easy exit market yet.

The strongest clean acquisition is Altos Labs buying Dorian Therapeutics. Dorian works around senescence and senotherapeutics, which fits directly into Altos’ cellular rejuvenation thesis. Granata Bio / Oviva is another strong transaction because ovarian aging is directly tied to female healthspan and reproductive longevity.

The rest of the biotech pattern is more complicated. Pulmatrix / Eos SENOLYTIX uses a reverse-merger structure with a financing reference. Minovia goes through a SPAC-style path. Daewoong acquired Turn Bio’s age-reversal assets, which looks more like a selective asset purchase than a large company exit. Those structures usually appear when capital is tighter or when assets need a more creative route forward.

Geroscience is not dead. Far from it. But the deal structures are telling us that the market is still difficult. Strong science can still get bought or financed, but broad premium M&A has not arrived.

If you want more recent data on this point, please see our latest longevity market report.

Is women’s longevity becoming a serious M&A theme now?

Yes. Women’s longevity is one of the more credible subthemes in recent longevity M&A.

Granata Bio acquired Oviva Therapeutics, which focuses on ovarian aging and female healthspan. That is a direct longevity-biotech angle, not a generic women’s wellness product. It ties aging biology to reproductive health and menopause-adjacent physiology.

Joi + Blokes acquired HerMD from the care-delivery side. HerMD brings menopause care, sexual health, hormonal wellness, gynecology, and virtual care. That makes the theme commercial, not just scientific. It shows buyers are interested in serving women’s aging through clinics and telehealth, not only through biotech pipelines.

The combination is what makes the theme strong. Oviva shows a science route. HerMD shows a patient-access route. When a theme appears in both R&D and care delivery, it usually has more staying power.

Women’s longevity is still early, but it has better foundations than many other longevity subcategories.

Are big companies buying longevity assets now?

Yes, but selectively. Large companies are entering longevity through specific entry points rather than buying the whole category.

Illumina is the biggest disclosed buyer in the dataset, with the SomaLogic transaction at $350 million upfront plus up to $75 million more. That is not a pure longevity deal, but it strengthens the multiomics measurement infrastructure that aging biology depends on.

Herbalife’s Pro2col / Pruvit / Link BioSciences transaction points to consumer nutrition and biomarker-driven protocols. Daewoong’s Turn Bio asset acquisition brings an established pharmaceutical company into cellular reprogramming and age-reversal technology. Oura, while private, is acting like a serious strategic acquirer in consumer health, with four relevant acquisitions.

Still, specialist platforms drive most of the count. Agentis, Novellum, Function Health, Infinite Epigenetics, Hone, Hundred Health, Chi Longevity, and reverse-merger vehicles make up much of the activity. This is not yet a market where large pharma or large healthcare incumbents set the whole agenda.

For now, big companies are entering through the edges: multiomics, nutrition protocols, wearables, and selected age-reversal assets.

Are longevity deal values transparent now?

No. Longevity M&A is still very opaque on deal value.

Out of 25 transaction records, 20 have undisclosed transaction value. That means 80% of the market gives no clean price. For anyone trying to analyze the sector, that changes the method. Dollar volume is much less reliable than deal count, segment mix, buyer behavior, and transaction structure.

The disclosed references also need caution. Illumina / SomaLogic is the cleanest large value reference at $350 million upfront plus up to $75 million more. Minovia’s $180 million SPAC reference and Pulmatrix / Eos’s $19 million financing reference are not classic cash acquisitions. Longevity Health / THPlasma had a $76.9 million reference, and Longevity Health / 20/20 had an approximately $50 million reference, but both were cancelled.

That creates a slightly uncomfortable conclusion: the most visible numbers can overstate the real closed market. The best analysis has to focus on what buyers are acquiring, not just what headline values get announced.

If you want more recent data on this point, please see our latest longevity market report.

Are failed deals a warning sign for longevity M&A now?

Yes, but the warning is specific. The riskiest area is not clinic roll-ups or small capability acquisitions; it is public-market recombination deals.

There are 2 cancelled transactions in the 24-month window, and both involve Longevity Health Holdings. First came the planned combination with 20/20 GeneSystems / 20/20 BioLabs. Then came the THPlasma reverse-merger transaction, which was also cancelled later in 2025.

The THPlasma case is especially useful because it had a lot of detail: plasma-center expansion, sales-agreement references, projected revenue, and transaction-value references. Even with that level of detail, the deal did not close.

That is why we should treat reverse mergers, SPAC-style routes, and public microcap combinations differently from normal acquisitions. Some may still work, but they often carry financing, shareholder, listing, or execution risk that a clean strategic acquisition does not.

The failed deals do not invalidate the longevity M&A market. They show exactly where the market is weakest.

Are buyers building full longevity platforms now?

Yes. The best buyers in longevity are clearly assembling platforms, not just collecting small assets.

Agentis is building a clinic platform. Mantality gives it the base, while Arete and BioDesign add more performance medicine and personalized longevity capabilities. The pattern is repeatable, and that matters in a fragmented services market.

Oura is building a health-data platform. Veri adds metabolic context, Sparta adds performance analytics, Doublepoint improves device interaction, and Galen AI connects clinical records and labs. The acquisitions fit together better than they look at first glance.

Function Health and Infinite Epigenetics are building measurement platforms. Function adds imaging to labs through Ezra. Infinite adds Tally’s consumer brand and recommendation layer to epigenetic testing. Hundred Health adds BellSant’s research and personalization data to an AI health product.

The most interesting buyers are not simply adding “longevity exposure.” They are filling gaps in a system: how to acquire users, deliver interventions, measure outcomes, personalize recommendations, and keep people engaged over time.

So what is the latest update on longevity M&A now?

When we put all the recent longevity M&A activity together, the market is active, but more selective than it was a year ago.

The headline numbers are clear: 25 transaction records over 24 months, with activity falling from 15 deals in the previous 12 months to 10 deals in the last 12 months. That is a 33% decline. The market is not accelerating. Still, the last 6 months produced 7 deals, so this is not a dead category either.

The deeper pattern is more useful. Buyers are moving toward clinics, diagnostics, biological-age testing, full-body MRI, metabolic data, clinical-data integration, women’s healthspan, and selected aging-biology assets. The softer longevity stories are less visible in recent M&A. The useful, measurable, billable parts of longevity are what buyers keep pursuing.

All everything considered together, longevity M&A has cooled, but it has also become more serious. The market is moving away from broad anti-aging storytelling and toward the infrastructure needed to deliver, measure, and personalize longevity.

If you want more recent data on this point, please see our latest longevity market report.

Check

Current status	Longevity M&A is real, with 25 transaction records over the last 24 months. The market is active, but still early and fragmented.
Recent acceleration	Activity has slowed. The last 12 months had 10 deals versus 15 in the previous 12 months, a decline of about 33%.
Last 6 months	The market is still moving, with 7 transaction records in the last 6 months. The pace is lower, but the deals are more targeted.
Main deal type	Buyers are mostly buying capabilities: clinics, diagnostics, data, biological-age testing, imaging, and selected aging-biology assets.
Clinic consolidation	Clinics are one of the clearest roll-up areas. Agentis, Novellum, Hone, Chi Longevity, and Joi + Blokes all support this pattern.
Wearable consolidation	Oura is the standout acquirer, with 4 relevant acquisitions. Its deals show wearables moving toward preventive-health infrastructure.
Diagnostics consolidation	Diagnostics is becoming central. Function / Ezra, Infinite / Tally, Illumina / SomaLogic, and Hundred / BellSant all point toward richer measurement.
Biotech signal	Geroscience biotech remains strategically interesting, but many deals use reverse mergers, SPAC routes, or asset sales instead of clean premium takeovers.
Women’s longevity	Women’s longevity is now a credible M&A theme. Oviva and HerMD show activity in both science and care delivery.
Buyer landscape	Specialist platforms still drive most transaction count. Larger companies are entering selectively through multiomics, nutrition protocols, wearables, and age-reversal assets.
Value transparency	Deal values are mostly undisclosed. 20 of 25 records have no clean transaction value, so deal-count and segment analysis matter more than total dollar volume.
Execution risk	Failed deals are concentrated but important. Longevity Health had two cancelled transactions, showing higher risk around public-market recombination deals.
Final status	Longevity M&A has cooled, but it has become more serious. Buyers are focusing on the infrastructure needed to deliver, measure, and personalize longevity.

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living "market pitch" documents for emerging markets: AI, synthetic biology, new proteins, and more. Instead of outdated PDFs or hallucinated LLM answers, our clients get a clean, visual, always-updated view of what's really happening: key players, deals, regulations, and signals that matter. Learn more about us.